Prepare to overcome your supply issues in 2022 by developing a high-performing supply chain for the cGMP chemicals critical to your biologic manufacturing. Download now!
Producers of the world's top COVID-19 vaccines say they are moving quickly to test their shots against the new omicron variant. They also are developing shots tailored to the new strain. Moderna said it has a three-pronged strategy to address the threat.
The PerkinElmer Lead Discovery Premium Biotech Bundle empowers you to find and understand trends and outliers in your data to ensure successful candidate selection. On the AWS Cloud, affordable, easy to deploy. Learn more.
With the omicron variant on the horizon, diagnostic companies are racing to determine whether the coronavirus’ latest mutations will hinder the performance of their screening tests. Companies including Thermo Fisher Scientific, Qiagen and Co-Diagnostics have stated that their PCR tests are not affected by the new strain.
As Fierce Biotech reported out the aftermath of the controversial approval of Biogen’s Aduhelm, we discovered a common thread at many of the top pharma companies who are working on the most advanced treatments in development: women. We wanted to know—how have they kept going?
On the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign companies Novo Nordisk, Sanofi and Eli Lilly are taking a beating in the key market.
The turnover rate among support staff for people living with intellectual or developmental disabilities continues to climb, despite people with these disabilities being significantly more at risk of dying from COVID-19.
The efficacy of Merck’s COVID-19 antiviral has fallen sharply. While most Americans were sleeping off Thanksgiving, Merck revealed the relative risk reduction fell from 50% to 30% in the final analysis of its phase 3 data, sending its stock sliding down.
Sixty-one bipartisan lawmakers told CMS Administrator Chiquita Brooks-LaSure that they "do not support" the repeal of the Medicare Coverage of Innovative Technology final rule, citing patients' reduced access to novel products.
After Amgen earlier this year suffered a third consecutive loss in its high-profile PCSK9 patent feud with Sanofi and Regeneron, the company faced two choices: appeal further or drop the issue. Not content to play sitting duck, Amgen has asked the Supreme Court to step in and review the case.
As GE prepares to spin off its healthcare business into a separate entity, the soon-to-be standalone company is forging ahead in its quest to develop a broad range of artificial intelligence tools designed to overhaul and revamp existing hospital practices.
UnitedHealth Group's Margaret-Mary Wilson, M.D., is stepping into the role of chief medical officer to lead the company's clinical innovations, focusing particularly on improving health equity.
It was a black Friday indeed for Ocugen, which revealed in the early morning hours after Thanksgiving that the FDA placed a clinical hold on its COVID-19 vaccine.
If BD’s ongoing hiring spree is any indication, the medtech giant—which recently reported nearly 20% growth in revenue for its fiscal year 2021—seems to be aiming to make an even bigger splash in 2022.
